



**CSL Limited**  
ABN: 99 051 588 348  
45 Poplar Road Parkville  
Victoria 3052 Australia  
T +613 9389 1911  
F +613 9389 1434  
[CSL.com](https://www.csl.com)

# ASX Announcement

---

For immediate release

28 March 2023

## CSL European Investor Site Tour Presentations

The presentation materials to be used for an Investor Site Tour being conducted by CSL (ASX:CSL; USOTC:CSLLY) in Europe this week are attached for the information of investors.

Authorised By

**Fiona Mead**  
Company Secretary

---

For further information, please contact:

**Investors:**

**Bernard Ronchi**  
Investor Relations  
CSL Limited  
P: +61 3 9389 3470  
E: [bernard.ronchi@csl.com.au](mailto:bernard.ronchi@csl.com.au)

**Media:**

**Bernadette Murdoch**  
Communications  
CSL Limited  
P: +61 449 950 745  
E: [Bernadette.murdoch@csl.com.au](mailto:Bernadette.murdoch@csl.com.au)

A woman with blonde hair, wearing clear safety glasses and a white lab coat over a green shirt, is shown in profile, looking down at a piece of laboratory equipment. The background is a bright, out-of-focus laboratory setting.

# CSL

Investor Tour,  
CSL  
Behring/Vifor  
European  
Operations

March 2023

# Legal Notice

## IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, **CSL**) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange (**ASX**), available at [www.asx.com.au](http://www.asx.com.au). This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", "project", "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.


The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, advances in environmental protection processes, uncertainty and disruption caused by the COVID-19 pandemic and CSL's ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

## TRADEMARKS

Except where otherwise noted, brand names designated by a <sup>TM</sup> or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

# CSL is expanding our capabilities by building an integrated, world-class network of internal sites as well as contract manufacturers, with focus on Reliability, Quality, Cost, Innovation and Safety



- **CSL Behring**  
King of Prussia, U.S.  
Kankakee, U.S.  
Pasadena, U.S.  
Bern, Switzerland  
Broadmeadows, Australia  
Marburg, Germany  
Wuhan, China

- **CSL Plasma**  
Boca Raton, U.S.
- **CSL Seqirus**  
Cambridge, U.S.  
Holly Springs, U.S.  
Summit, U.S.  
Liverpool, U.K.  
Maidenhead, U.K.  
Parkville, Australia

- **CSL Vifor**  
Zurich, Switzerland  
St. Gallen, Switzerland

- ▲ **Regional Sales and/or Distribution**

- **Key CMO Partners**  
Abbvie  
Alphasigma  
Corden  
Fresenius Kabi  
Thermo Fisher  
UniQure

**Melbourne, Australia**  
CSL Headquarters

# CSL Behring Manufacturing Sites



**Bern, Switzerland (1,800+ employees)**

**Products:** Immunoglobulins (IG), Albumin anti-D-hyperimmune, potential CSL112



**Kankakee, US (1,500+ employees)**

**Products:** Albumin, IG intermediate paste, Coagulation factors, alpha1-proteinase inhibitor, PCC & C1 intermediates



**Broadmeadows, Australia (1,300+ employees)**

**Products:** IG, Albumin, potential CSL112 and Coagulation factor toll manufacturing services for Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan



**Wuhan, China (240+ employees)**

**Products:** Albumin & Immunoglobulins for the Chinese market.



**Marburg, Germany (2,900+ employees)**

**Products:** Albumin, IG & Albumin paste, Coagulation factors and Hyperimmunes



**Lengnau, Switzerland (Operated by Thermo Fisher)**

**Products:** Idelvion and other recombinant products  
Scheduled to begin manufacturing in FY24

# Donor to Patient



CSL Plasma Center



Knoxville, TN



Goettingen, DE



Indianapolis, IN



Dallas, TX



Schwalmstadt, DE



Bern



Marburg



Kankakee



Broadmeadows

## IMED Exchange

Fraction V Paste  
 Fractionation IV Paste (CSL 112)  
 Precipitate C Paste  
 I+II+III Paste / II+III Paste  
 Precipitate A

II+II+III Paste  
 I+III Paste

Rhophylac  
 Cryoprecipitate

DEAE Eluat; QAE-AS Precipitate  
 Cryoprecipitate; Albumin Paste

Voncento  
 Semi-finished

Kybernin  
 Water for injection vials

Fraction V Paste  
 Precipitate A  
 I+II+III Paste

WFI vials  
 II/III Paste

Cryoprecipitate



Bern



Marburg



Kankakee



Broadmeadows

## Key Products

Privigen  
 Alburex  
 Hizentra  
 ...


## Specialty Products

Human Albumin,  
 HAEGARDA, Beriplex,  
 Beriplast, AFSTYLA,  
 Idelvion, ...

Zemaira  
 Alburex  
 ...

Privigen  
 Alburex  
 Toll  
 ...


# CSL Behring Operating Model



# Tier Meeting Cascade & Reliability Room

We are driving transparency, action and accountability across the CSL Behring business unit through our tier escalation process. The regular Tier Meetings are focused on operational performance review and escalations with a strong focus on reliable supply to patients.

Tier Meetings ensure a daily cascade of critical issues within the site involving all operational functions. Supply "smoke signals" are elevated to the weekly Reliability Room ensure appropriate resolution and/or contingency planning.



People



Safety



Quality



Reliability



Innovation

# CSL Behring

## Operational Highlights




### Manufacturing

- Broadmeadows and Marburg new base fractionation facilities licensed and operational
- Continued investment in short and long term yield/capacity initiatives:
  - Albumin in Broadmeadows
  - IgG in Bern



### Plasma Collections 1H23

- Strong increase in plasma collected +36% with levels now 10% above pre-pandemic
- Mexico border re-opened with collections recovering strongly
- 7 new centers in US and 1 in Germany
- Continued adoption of technology
  - CSL Plasma donor app – downloads >2.5m
  - Online health questionnaire
- RIKA program commenced





**Network  
Capacity**



**Asset  
Management**



**Financial &  
Resource  
Optimization**



**Risk  
Management**

Our focus on **Network Strategy** ensures both a **resilient and reliable** Supply Chain

# Network Resiliency

*Ensuring safe, reliable product supply for our patients across a complex, global supply chain.*

## Plasma

- **Optimizing** annual center expansions to align with IG demand & yield forecasts.
- **Balancing** new builds vs. center efficiency vs. donor marketing & remuneration

## Bulk

- Balancing CSL **investment** across sites and broadening **knowledge** of key products to across the network
- Timing new capacity to ensure **supply** & maximize **ROIC**

## Fractionation

- Adding right-time capacity and balancing risk
- Optimizing supply chain.

## Fill / Finish

- **Leveraging relationships** with key partners to find the right expertise, optimize production flexibility & ROIC
- **Reducing** Supply Chain Lead Times



**Capital Investment / ROIC**



**Supply Chain Complexity**



**Physical Asset Lifecycle**



**Regulatory**



**Balancing of Project Work**



**Demand Variability**



**Risk - Supply / Geopolitical**



**People & Expertise**



**Sustainability**

# CSL has continued to execute against our growth strategy



**Marburg**

**Fractionation Capacity**



**Broadmeadows**

**Fractionation Capacity**



**Bern**

**Immunoglobulin Capacity**

Superb execution by the project teams enabled approval of Marburg and Broadmeadows fractionation projects via a **CBE-30** in the U.S. and utilization of non-injectable plasma for qualification, delivering an **approval** faster than conventional timelines.

# Key CSL Behring Capital Projects

*CSL conducts annual Long-Term Demand & Capacity Forecasts to ensure optimal timing for CapEx projects*

## Technology

- Rika Device Rollout
- New Quality Management System (Veeva)

## Bulk & Finish

- Zemaira Fill – TFS, US
- Albumin Bulk & Fill – BMW, AU
- CSL112 Bulk & Fill – Bern, CH
- IG Bulk – planning

## Fractionation

- Marburg & Broadmeadows Production Ramp In Progress
- CSL112 paste – Broadmeadows, AU
- Base Frac – planning

## Other

- Asset retirement & replacement



Optimizing Spend



Maximizing ROIC



Balancing Risk



Leveraging CMOs




Ensuring Growth

# Annual CapEx Investment\*

*Network Strategy & Portfolio Management continue to focus on optimization of CapEx spend*

\$Billion USD



-  Optimizing Spend
-  Maximizing ROIC
-  Balancing Risk
-  Leveraging CMOs
-  Ensuring Growth

# Enterprise Wide Quality Framework

**Our Commitment to Quality**

At CSL, we are Driven by Our Promise™ and guided by our Values: **Patient Focus, Innovation, Integrity, Collaboration** and **Superior Performance**. These are evident in every aspect of our global business and support our Commitment to Quality.

CSL is committed to protecting public health and improving and saving the lives of patients with rare and serious diseases through the development, manufacture and reliable supply of high-quality medicines.

Our Quality Management System provides the framework for ensuring adherence to global regulatory requirements for the entire product life cycle across the globe. The QMS contains policies and procedures to manage our business processes across all functions, our partners and suppliers, product manufacture, distribution and sales, and the ongoing monitoring of product safety in the field.

People are the core of CSL's quality culture. CSL employees recognize their individual responsibility to insist on the quality and safety of our products, protect public health and ensure the safety of our plasma donors. Engagement and education of CSL employees is key to sustaining the highest standards throughout the company.

The commitment of our people to Quality within our Values-based work environment is essential to delivering on our promise to the public and our patients.

**Paul Perreault**  
CEO and Managing Director  
September 2019

Driven by Our Promise™ 

- A standardized, and compliant Quality Management System (QMS) for all CSL Limited businesses
- Provides CSL standards across the CSL network aligned with regulatory requirements
- Provides consistency towards regulators and authorities visiting our locations globally



CSL Behring CSL Plasma

CSL Seqirus CSL Vifor



One R&D



## Quality Facts and Figures FY22

- CSL was subject to 406 good manufacturing practice (GMP) regulatory agency inspections around the world with no impact to our licenses
  - 28 inspections of our manufacturing facilities
  - 378 inspections of CSL Plasma centers
- CSL performed 676 Quality Audits of our suppliers to assure continued consistent high-quality materials from our partners
- 15 Corporate GXP Internal Audits have been completed across the CSL Group since the commencement of the program 2 years ago



# Quality Culture & Continuous Improvement

## Investments in Quality:

State of the art automation in manufacturing & laboratories

Equipment and facilities to meet new sterile product regulations

Modernized training assets for our plasma centers



I make Quality a priority by discussing it openly, honestly, and frequently.


**Liza Kudach**  
Quality Systems & Compliance



# Our 2030 Strategy in 4 Words:

## Driving Sustainable, Profitable Growth

- 1. Focusing** – in therapeutic areas where we excel
- 2. Innovating** – across our organization
- 3. Delivering** – reliable supplies of our products as efficiently as possible
- 4. Growing** – our pipeline with sustainable, trusted R&D platforms, and
- 5. Transforming** – our digital intellect and technologies



CSL Behring

# Biopharma in the Heart of the Capital

2023




**Driven by Our Promise**

02

Welcome to Bern!

# Our Pioneering on the Bern Site



# Functions in Bern



## E2E Operations

Fractionation  
Bulk  
Filling & Visual  
Inspection  
Packaging

Maintenance & Utilities  
Engineering  
Environment, Health &  
Safety (EHS)  
Quality & Quality  
Control



## Commercial Operations

Commercial Operations  
Intercontinental  
  
Commercial Operations  
Switzerland



## R&D

CSL Behring Biologics  
Research Center  
(sitem-insel)  
  
Plasma Product  
Development  
  
Global Regulatory  
Affairs



## Enabling Functions

Finance  
I&T  
HR  
Legal  
Communications

# Our People



## Diverse Workforce

- **1800** employees:
- **39%** women / **61%** men
- **65** nationalities
- **8.7** years of average tenure
- **43** years of average age




## Talents & Culture

- **Early career concept**
  - 40 apprentices, trainees and internships
- **Gender equality**
- **Equal pay** certification



# Bern Leading Sustainable Technology to Reduce Environmental Impact

- Since 2016, we have savings of about 6,000 MWh of energy and about 1,000 tons of CO<sub>2</sub>. This corresponds to 9% energy and 11% CO<sub>2</sub> savings compared to 2015.
- We have been using electricity exclusively from hydropower for several years.



# Products Bern



# Product Portfolio CSL Behring – Northern Hemisphere

---

## Critical Care

---

Albumin Solutions

**Human Albumin Behring®**

**Alburex®**, AlbuRx®, Albumex®

Albuminar®

Inhibitors

Beriner® P, Haegarda®

Kybernin® P

Other Trauma Therapies

Beriplex® P/N, Coaplex, Kcentra®

RiaSTAP®, Haemocompletan® P

Thrombotrol®

Prothrombinex®

---

## Wound Healing

---

Beriplast® P Combi-Set

Fibrogammin®, Corifact®, Cluvot®

Fibrinogen a.s.

---

## Immunology

---

**Polyvalent Immunoglobulins**

**Privigen®**

**Hizentra®**

Carimune® NF

Sandoglobulin®

Intragam®

Evogam®

Hyperimmunes

**Rhophylac®**, Rhesogam

CytoGam®

Beriglobin® P

Berirab® P

Hepatitis B IG P Behring®

Tetagam® P

---

## Pulmonology

---

Zemaira®

Respreeza®

---

## Coagulation

---

Plasma-derived factor II

Human Thrombin a.s.

Recombinant factor VIII

Afstyla®

Recombinant factor IX

Idelvion®

Factor VIII:C/von Willebrand factor

Haemate® P, Humate® P, Biostate®

Plasma-derived factor VIII

Beriate® P, Monoclate® P, Biostate®

Plasma-derived factors X

Factor X P Behring®

---

## Seqirus

---

Afluria®

Flucelvax® Tetra

**Green:** products manufactured in Bern

# Bern Products

## Immunoglobulins



### Privigen®

25/50/100/200/400mL  
3 years by +2 to +25°C



### Hizentra®

5/10/20/50mL  
30 months by +2 to +25°C



### Hizentra® PFS

5/10/20mL  
30 months by +2 to +25°C



### RhoPhylac®

2mL  
3 years by +2 to +8°C

## Albumin



### Alburex® 5%

100/250/500mL

### Alburex® 20%

50/100mL

### Alburex® 25%

50/100mL  
3 years by +2 to +30°C

## CSL112



Promotes cholesterol removal leading to plaque stabilization

Reduction of recurrent heart attacks and stroke

**Current Products**

**Future Product**




Serving patients and people in 100+ countries

03


## CSL Behring's Presence & Innovation in Bern



# Facilities Site Bern




# Investments




# Efficiency & Innovation




**More batches**



**Increase batch size**



**Increase yield**



## Growth IgG

### **IG Capacity**

- Project delivered, ahead of schedule, on budget
- IgLAB Module V & VI IG capacity:
- Max capacity utilization demonstrated (14 batches per week)

### **Bulk & Filling Capacity**

- Upgrade existing Phase 3 CSL112 bulk facility and install new filling line and lyophilises
- Minimize capital investment at risk
- Bern's yearly production will supply approx. 80'000 patients per year

### **Automation**

- Our new manufacturing site for visual inspection, secondary packaging and storage of intermediate and finished products
- Transition into fully automated final manufacturing from incubation to delivery

# CSL R&D in Switzerland

**Plasma Product Development**  
GPS, CMC, BioProcess Sciences, BioAnalytical Science, Breakthrough Launchpad, Primary Packaging & Medical Devices


**Global Regulatory Affairs**  
GRA CMC, GRA OpX, GRA GPS, GRA Policy & Intelligence

**300+ (500+)**  
R&D **employees**

Wankdorfstrasse

Feusi

Sitem-Insel



**3 (6)**  
**sites**

**17**  
**collaborations** with academic institutions and hospitals in EU and CH

**225**  
**scientific papers** published with our collaborators since 2015

**Other R&D functions**  
Project Management, Pharmacology & Translational Development, Clinical Safety, Global Licensing, IP

**Research**  
Biochemistry, Gene Therapy Research, Preclinical Innovation, Translational Research, Research External Innovation


**32**  
**nationalities**

**56**  
**languages**

# R&D Cooperations



# Memberships & Community Commitments



05

Thank you for your  
attention!



# Welcome to Marburg

Investor Tour  
28 March 2023


Michael Schröder,  
Site Head Marburg

The picture shows Kathrin Schön, one of our HAE patients



**CSL Behring  
Marburg  
Operations**  
Site Overview


# Focus on Reliable Supply




# Marburg at a Glance




# Behringwerke Campus Main Plant




# Behringwerke Campus Görzhausen



# Our Technical Capabilities



# Focus on Inframarginals



# Product Portfolio of CSL Behring – Northern Hemisphere

## Critical Care

Albumin solutions

**Human Albumin Behring®**

Alburex®, AlbuRx®, Albumex®

Albuminar®

Inhibitors

**Beriner® P, Haegarda®, Beriner® SC®**

**Kybernin® P**

Other trauma therapies

**Beriplex® P/N, Coaplex, Kcentra®**

**RiaSTAP® Haemocompletan® P**

Thrombotrol®

Prothrombinex®

## Wound Healing

**Beriplast® P Combi-Set**

**Fibrogammin®, Corifact®, Cluvot®**

**Fibrinogen active substance**

## Immunology

Polyvalent immunoglobulins

Privigen®

Hizentra®

Carimune® NF

Sandoglobulin®

Intragam®

Evogam®

Hyperimmunes

**Rhophylac®, Rhesogam**

CytoGam®

**Beriglobin® P**

**Berirab® P**

**Hepatitis B IG P Behring®**

**Tetagam® P**

## Pulmonology

Zemaira®

**Respreeza®**

## Coagulation

Plasma-derived factor II

**Human Thrombin active substance**

Recombinant factor VIII

**Afstyla®**

Recombinant factor IX

**Idelvion®**

Factor VIII:C/von Willebrand factor

**Haemate® P, Humate® P, Biostate®**

Plasma-derived factor VIII

**Beriate® P, Biostate®**

Plasma-derived factors X

**Factor X P Behring®**

Gene therapy

Hemgenix®

## Seqirus

**Afluria®**

**Flucelvax® Tetra**

# Take a look inside our manufacturing



# Focus on our People

- Lean and agile culture and working environment
- Embedded in the community
- Well-established relations with universities
- Focus on future talent



Promising  
**FUTURES**

# Add Green to CSL's Red


## "Phoenix" – New Base Fractionation Facility

- Investment: USD 470M
- Sustainable and energy-efficient planning
- Highest KfW-credit in history (EUR 250M)
- Fractionation capacity increased by 4

## M600 – R&D Cube

- Investment: USD ~ 170M
- Highest energy standards (ice storage combined with heat pump)
- 500 R&D employees under one roof





Marburg's St. Elizabeth's Church lights up for "Rare Disease Day" 28 February 2023



CSL Vifor




**Elena is  
impacted by  
iron deficiency**

# Maximizing the Iron Opportunity

CSL Vifor

Hervé Gisserot  
General Manager CSL Vifor

# Our Future is Built on the Framework of Our Rich Iron Heritage



# We are a Global Leader in Iron Replacement and Nephrology Therapies

## Iron Replacement

Further expansion in anemia; growth through HF, PBM and geographic expansion



## Nephrology

Launching the next generation of therapies addressing kidney disease progression



### In Market



### Pipeline

Heart failure opportunity & geographic expansion

SNF-472  
vadadustat<sup>6</sup>

Sparsentan<sup>7</sup>  
INS-3001 vamifeport

**Note:** HF = heart failure. PBM = patient blood management. | <sup>1</sup> Licensed from F. Hoffman-La Roche AG. | <sup>2</sup> Licensed from Pfizer Inc. | <sup>3</sup> Licensed from ChemoCentryx, Inc. | <sup>4</sup> Licensed from OPKO Health, Inc. | <sup>5</sup> Licensed from Cara Therapeutics, Inc. | <sup>6</sup> Licensed from Akebia Therapeutics, Inc., subject to certain conditions and limited to selling Vadadustat to certain providers within the US dialysis market. Status pending - Complete Response Letter received from FDA due to safety concerns. | <sup>7</sup> Licensed from Traverre Therapeutics, Inc.

# Iron Replacement:


CSL Vifor's Largest Franchise

	Therapy Group	Sales <sup>1</sup> \$m
Ferinject/Injectafer	Iron	315
Mircera	Dialysis	258
Velphoro	Dialysis	77
Venofer	Iron	74
Veltassa	Non Dialysis	49
Maltofer	Iron	36

<sup>1</sup>~5 months revenue contribution (Acquired 9<sup>th</sup> August 2022)

## 1H23 revenue by therapy group<sup>1</sup>

In \$m





The number of ID<sup>1</sup> patients without IDA<sup>2</sup> is estimated to be more than twice as many as the number of IDA patients<sup>3,4</sup>


## What is Iron Deficiency?

Significant global prevalence

**Iron  
Deficiency  
>3B people**

**ID Anaemia  
~1.2B people<sup>5</sup>**

**1.** ID = Iron Deficiency; **2.** IDA = Iron Deficiency Anaemia, occurs when ID is sufficiently severe to reduce erythropoiesis; **3.** Iron deficiency (Blood. 2019;133(1):30 – 39) – Anaemia still affected one third of the population, with approximately half of the cases resulting from iron deficiency. The estimate is that 1.24 billion individuals experience iron deficiency anaemia. The global prevalence of iron deficiency without anaemia remains elusive, although the suggested figure is at least double that of iron deficiency anaemia; **4.** These numbers are estimates, most studies either have a geographical focus or are done in specific subpopulations. **5.** Blood. 2014 Jan 30;123(5):615-24.




## Significant untapped potential with Ferinject®/Injectafer®

Majority of patients yet to be diagnosed & treated (EU5 only)

### A market Leader in High Dose IV Iron Segment<sup>1</sup>

>1.2B CHF in-market sales in 2022

- 28% market share of overall Iron market (Global In-Market Sales (MAT Q4 2022))
- 47% market share in IV iron segment
- More than 22 million patient years of exposure




<sup>1</sup> IQVIA MIDAS Quarterly panel, GERS, Insight Health, DN, DLI; Average 2022 exchange rates have been applied. ID = Iron Deficiency. IDA = Iron Deficiency Anaemia.

# Priorities to accelerate Ferinject®/Injectafer® growth


## Areas of focus

---

Focused targeting, amongst the many different patients suffering from ID and IDA



Heart Failure (HF)



Chronic Kidney Disease



Patient Blood Management (PBM)

## Strategic priorities

---

### Maximise penetration ex-US

- Explore potential revenue synergies with CSL Behring on PBM
- Geographic expansion

### Maximise penetration in the US

- Improve access
- Successfully launch HF indication with our partner American Regent (Daiichi Sankyo)

### Explore other avenues for product differentiation



CSL Vifor

# CSL Vifor St. Gallen, Home of Iron


29 March 2023

Hans-Martin Müller


Head Manufacturing  
Iron & Strategic Projects

# Employees are our most valuable asset, empowered to creating their own career journey with us


## Head Count



## Share of FTE's



## Time with CSL Vifor



**33%**



Share of women

- 10% Director +
- 37% Manager

**62%**



Share of educational attainment at "tertiary level" (Universities & higher vocational training)

**27**




Different nations

**10**



Apprentices

# CSL Vifor's rich heritage dates back to 1872 when the success story of iron began in St. Gallen



# All iron products were discovered, developed and are produced in St. Gallen to this date



# The manufacturing site in St. Gallen focuses mostly on API production of its iron products




> API manufacturing in St.Gallen




> FP Contract Manufacturing

# Complex manufacturing turns iron ore into the active pharmaceutical ingredients (API) of our iron therapies



# Over 1,000 tons of iron based API's are produced in St. Gallen per year



## FDA-Inspection History

2000	PAI Venofer
2007	GMP Conformity Without deficiencies
2010	GMP Conformity Without deficiencies
2012	PAI Velphoro Without deficiencies
2016	GMP Conformity Without deficiencies
2021	GMP Conformity, (Mail Audit) Without deficiencies

# Best Use of nearby sustainable Energy Sources

## Participation in two River Power Plants since 2018




## Future use of Communal District Heating



Aim: Reduction of CO<sub>2</sub> Footprint by >80%

# Learn more about our iron expertise on today's tour through the St. Gallen site



- 1** The iron exhibition
- 2** From rock to iron dust
- 3** Take iron seriously
- 4** Nanomedicines
- 5** In the heart of the factory
- 6** The success story continues

# Behavioral Rules for the Tour


Do not take photos on the site.

---

Wear the specified personal protective equipment correctly during the tour.

---

Do not touch any pipes, apparatus or surfaces.



# Our local experts will guide you through the iron experience today



Group "Green"

## Hans-Martin Müller

Head Manufacturing  
Iron & strategic  
projects

- With CSL Vifor for 23 years
- PhD in Organic Chemistry from the Federal Institute of Technology (ETH) Zurich, Switzerland



Group "Blue"

## Manuel Senn

Site Head

- With CSL Vifor for 15 years
- Holds an BSc in Chemistry, focus on biochemistry, from the University of applied science in Winterthur, Switzerland



Group "Yellow"

## Dominic Lampert

Head of Production

- With CSL Vifor for 13 years
- Holds a diploma in Industrial Engineering and Management from University of Mittweida, Germany



Group "Red"

## Markus Sonderegger

Head Quality  
Operations API,  
Manufacturing

- With CSL Vifor for 12 years
- holds a Master in Biological Science from the University of Innsbruck, Austria



Group "Purple"

## Philipp Bachmann

Global Head Quality  
Management,  
TechOps

- With CSL Vifor for 23 years
- holds a Master in Biochemistry from the Swiss Federal Institute of Technology in Zürich (ETH)